Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Marietta, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, a leader in placental biologics, announced it will report its first-quarter financial results for the period ending March 31, 2023, on May 2, 2023, after market close. A conference call and webcast to discuss these results will follow at 5:00 p.m. Eastern Time. Investors can access the call through U.S. and international lines provided in the announcement. A replay will be available on the company’s website for 30 days post-event. MiMedx focuses on developing placental tissue allografts and has supplied over two million products to address clinical needs in advanced wound care and surgical recovery. The company is also advancing a late-stage pipeline targeting pain reduction and improved function for knee osteoarthritis patients.
MiMedx Group (Nasdaq: MDXG) announced the departure of CFO Peter M. Carlson on March 23, 2023, as he pursues other opportunities. The company has initiated a search for a new CFO, with Carlson assisting during the transition. His tenure at MiMedx significantly improved the company's finance and accounting, helping to raise debt and equity while avoiding delisting. MiMedx specializes in placental biologics, providing allografts for advanced wound care and surgical recovery. The company is committed to addressing unmet clinical needs and has delivered over two million allografts.
MiMedx Group, Inc. (MDXG) has praised the Office of Inspector General's recommendation for the Centers for Medicare and Medicaid Services (CMS) to expedite addressing issues related to Average Sales Price (ASP) reporting for skin substitute products. The OIG report highlights non-compliance from some manufacturers, impacting Medicare spending in private physician settings. MiMedx's products, EPIFIX® and EPICORD®, have been sold under transparent ASP-based rates, promoting equitable patient care. The report also encourages CMS to consider effective payment approaches and ensure compliance from manufacturers as a way to alleviate financial burdens on the Medicare Trust Fund.